ALB and COVID-19: In detail, in this study, we confirmed that a previously proposed threshold of 30 ng/mL can represent an optimal level in the context of COVID-19, over which a more benign disease evolution is expected, particularly in presence of normal albumins concentration, for patients younger than 70 years old and in absence of serious comorbidities.